News

Penthrox Regulatory Dossier accepted for review in Canada

Jun 15, 2017Mark EdwardsNews

15 June 2017

ASX ANNOUNCEMENT

Penthrox Regulatory Dossier accepted for review in Canada

Medical Developments International Limited (ASX: MVP) is delighted to announce that the regulatory dossier for Penthrox? submitted in Canada has now been accepted for review by the Canadian regulatory body, Health Canada.

Accepting the MVP dossier for review, triggers a milestone payment of CAD$0.25 million from MVP?s partner, Purdue Pharma (Canada).

MVP Chief Executive Officer, Mr. John Sharman said: ?This is another positive step towards globalizing Penthrox.?

'),document.contains||document.write(''),window.DOMRect||document.write(''),window.URL&&window.URL.prototype&&window.URLSearchParams||document.write(''),window.FormData&&window.FormData.prototype.keys||document.write(''),Element.prototype.matches&&Element.prototype.closest||document.write('')